Viral Conjunctivitis Drugs Market is estimated to be valued at US$ 293.7 Mn in 2021, and is expected to exhibit a CAGR of 4.7% over the forecast period | AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc

Overview

The conjunctiva is inflamed due to viral conjunctivitis. Infections with viruses such as human immunodeficiency virus, adenovirus, poxvirus, picornavirus, varicella zoster virus, and herpes simplex virus cause viral conjunctivitis. Pink eye illness is another name for it. The crimson eye, fluid secretion from the eye, and itching/irritation are all symptoms of viral conjunctivitis. Virus-induced conjunctivitis can develop into corneal keratitis. Indicative or pathogen medication for viral conjunctivitis is available.

Request PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1281

Impact of the COVID-19 Pandemic

On December 31, 2019, a COVID-19 infection was first detected in Wuhan, China. COVID-19 was designated a pandemic by the World Health Organization on March 11, 2020. According to the World Health Organization’s Coronavirus (COVID-19) Weekly Epidemiological Update, approximately 166,346,635 cases and 3,449,117 fatalities due to coronavirus illness (COVID-19) were recorded worldwide through May 21, 2021. The COVID-19 outbreak and subsequent lockdown in many nations across the world has had a financial impact on firms in all industries.

The COVID-19 outbreak has damaged the pharmaceutical industry’s whole distribution network, owing to severe lockdown in some locations. In the ongoing COVID-19 pandemic, therefore, demand for conjunctivitis medicines is rising, owing to an increase in the number of conjunctivitis cases recorded, in which conjunctivitis was the sole symptom in COVID-19 positive individuals.

Furthermore, the coronavirus pandemic has had an influence on the research, manufacture, and supply of medications, as well as the businesses of different healthcare corporations throughout the world. The epidemic has resulted in the shutdown of industrial enterprises, with the exception of those that manufacture vital goods, as well as disruptions in product supply chains.

The logistic chain and manufacturing operations in India, China, the United States, and other nations have been affected as a result of the shutdown, while countries such as Thailand, Indonesia, and Singapore are experiencing issues with medication and medical device shipping.

As a result of the decline in production and supply of the medications during the coronavirus (COVID-19) pandemic, the global viral conjunctivitis drugs market is anticipated to expand slowly over the forecast period.

The global viral conjunctivitis drugs market is anticipated to reach US$ 293.7 million in 2021, with a CAGR of 4.7 percent during the forecast period.

Over the projected period, the rising incidence of viral conjunctivitis instances is projected to fuel market expansion. During the forecast period, the growing number of viral conjunctivitis patients is estimated to fuel the expansion of the global viral conjunctivitis drugs market. Adenovirus is the most prevalent cause of viral conjunctivitis, accounting for up to 70 percent of occurrences, according to the National Center for Biotechnology in 2017.

Furthermore, the global viral conjunctivitis drugs market is anticipated to expand due to an increase in the number of research and development efforts aimed at enhancing the efficacy of viral conjunctivitis medicines throughout the forecast period. The first patient in the Phase II clinical study was dosed in 2019, according to iVIEW Therapeutics Inc., a clinical stage ophthalmology medication research firm.

Request For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1281

Due to the increasing frequency of viral conjunctivitis, rising healthcare spending may assist research and development efforts, which in turn may help the research and development of novel medicines for viral conjunctivitis. During the forecast period, this is projected to fuel the expansion of the global viral conjunctivitis drugs market. According to the Research America 2018 report, the United States government spent about 4.97 percent of GDP in medical and health research and development in 2016, and this grew to 5.03 percent in 2017. According to the National Bureau of Statistics, China’s research and development spending grew by 11.6 percent in 2017 compared to 10.6 percent in 2016, totaling US$ 280 million in 2017.

Market Taxonomy

• According to the class of drug: Antibiotics, Artificial tears, Steroids, Decongestants, Anti-Viral drugs, Anti-histamines, and NSAIDS.
• According to the type of virus: Enterovirus and Adenovirus.
• According to the distribution channel: Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies.

Restraints

The global viral conjunctivitis drugs market for viral conjunctivitis drugs may be hampered by rising consumer recalls and the lack of appropriate antiviral treatment. According to a study published in Ophthalmology in 2017, 83 percent of conjunctivitis patients went to primary care centers instead of seeing an ophthalmologist.

Buy This Research Study Report For Quick Access@ https://www.coherentmarketinsights.com/insight/buy-now/1281

Antibiotic treatment levels in the community for patients with infectious conjunctivitis in the United Kingdom range from 80 to 95 percent. As a result, the global viral conjunctivitis drugs market will increase depending on the performance of clinical studies and the launch of products for the treatment of viral conjunctivitis.

Regional Insights

Due to the increasing number of product releases, North America is projected to retain a prominent position in the global viral conjunctivitis drugs market throughout the forecast period. Bausch & Lomb released Alaway Preservative Free antihistamine eye drops on February 23, 2021. It is used to treat conjunctivitis-related irritation in the eyes.

Leading companies are focusing on obtaining patents for their products that are used to cure conjunctivitis, which is projected to fuel market expansion in Asia Pacific. The US Patent and Trademark Office granted Starpharma Holdings Limited, the Australian business, a patent for SPL7013 ocular drops for viral conjunctivitis in 2018. The firm received the patent for its wide applications for treating and preventing microbial diseases of the eye, such as adenoviral conjunctivitis, bacterial conjunctivitis, and other illnesses. The patent is valid until 2033.

Competitive Landscape

Key companies contributing in the global viral conjunctivitis drugs market are Panoptes Pharma Ges.m.b.H, Bausch Health Companies Inc., NanoViricides Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Okogen Inc., GlaxoSmithKline Plc., Johnson & Johnson, Novartis International AG, Nicox, and NovaBay Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Overview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Drug Class
     • Market Snippet, By Virus Type
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Algorithm for Clinical Approach to Suspected Acute Conjunctivitis
   • Associated/Predisposing Factors for and Typical Clinical Signs Of Conjunctivitis
   • PEST Analysis
   • Recommendations for Other Eye Disorder Treatment
   • Industry Trends
   • Pipeline Analysis
   • Key Highlights
   • Epidemiology
   • Algorithm for Classification of Viral Conjunctivitis based on Clinical Presentation
   • Drugs Pricing List
   • Reimbursement Scenario of Viral Conjunctivitis Drugs
   • Regulatory Scenario
   • Global Supply Chain Analysis
4.  Global Viral Conjunctivitis Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
   
   • COVID-19 Epidemiology
   • Impact of COVID-19 on Demand and Supply of Viral Conjunctivitis Drugs
   • Impact of Covid-19 on the Conjunctivitis Drugs Market
5. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2017-2028 (US$ Million)
   • Introduction
     • Market Share Analysis, 2021 and 2028 (%)
     • Y-o-Y Growth Analysis, 2018 – 2028
     • Segment Trends
   • Artificial tears
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Decongestants
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Anti-histamines
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • NSAIDS
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Anti-viral drugs
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Steroids
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Antibiotics
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
6. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2017 – 2028 (US$ Million)
   • Introduction
     • Market Share Analysis, 2021 and 2028 (%)
     • Y-o-Y Growth Analysis, 2018 – 2028
     • Segment Trends
   • Adenovirus
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Enterovirus
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Others
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
7. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2017 – 2028 (US$ Million)
   • Introduction
     • Market Share Analysis, 2021 and 2028 (%)
     • Y-o-Y Growth Analysis, 2018 – 2028
     • Segment Trends
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Retail Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Online Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
8. Global Viral Conjunctivitis Drugs Market, By Region, 2017 – 2028 (US$ Million)
   • Introduction
     • Market Share Analysis, By Region, 2021 and 2028 (%)
     • Y-o-Y Growth Analysis, For Regions, 2018 – 2028
     • Regional Trends
   • North America
     • Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Virus Type, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
       • U.S.
       • Canada
   • Latin America
     • Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Virus Type, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
       • Brazil
       • Mexico
       • Argentina
       • Rest of Latin America
   • Europe
     • Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Virus Type, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
       • Germany
       • U.K.
       • France
       • Italy
       • Spain
       • Russia
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Virus Type, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
       • China
       • India
       • Japan
       • Australia
       • South Korea
       • ASEAN
       • Rest of Asia Pacific
   • Middle East
     • Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Virus Type, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
       • GCC
       • Israel
       • Rest of Middle East
   • Africa
     • Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Virus Type, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Country/Region, 2017 – 2028 (US$ Mn)
       • South Africa
       • Central Africa
       • North Africa